Professor Will Herrington
Websites
-
Medical Research Council-UK
Professor David Kerr Clinician Scientist Award, 2018-2022
-
Kidney Research UK
Professor David Kerr Clinician Scientist Award, 2018-2022
- Health Data Research UK
-
British Heart Foundation
Centre of Research Excellence
- The EMPA-KIDNEY trial
- Mexico City Prospective Study
- The SHARP trial
- Cholesterol Treatment Trialists' Collaboration
- The UK-HARP3 trial
- The 3C trial
-
Oxford Kidney Unit
Honorary Consultant Nephrologist
-
Kidney Diseases: Improving Global Outcomes (KDIGO)
Controversies Conference on Challenges in the Conduct of Clinical Trials in Nephrology
-
UK Renal Trials Network
Chair
Will Herrington
MA, MBBS, MD, FRCP, FERA
Professor of Trials and Epidemiology of Kidney Disease, Renal Studies Group
- Professor of Trials and Epidemiology of Kidney Disease
- Honorary Consultant Nephrologist, Oxford Kidney Unit
BIOGRAPHY
Professor Will Herrington is a clinician scientist based at the Nuffield Department of Population Health, University of Oxford and a practising Honorary Consultant Nephrologist at Oxford Kidney Unit. He jointly leads the Renal Studies Group which he joined in 2010 as a Clinical Research Fellow and trained on landmark renal trials (SHARP, 3C and UKHARP3).
He is Chief Investigator of the EASi-KIDNEYTM trial (which is due to start recruitment in 2024) and the EMPA-KIDNEY trial which tested the effects of empagliflozin 10mg versus placebo on cardiorenal outcomes in 6609 people with chronic kidney disease with and without diabetes.
The trial has now entered a post-trial observational follow-up phase and is developing health economic analyses. The biobank of leftover biological samples is being analysed to better understand the mechanism of action and metabolic effects of sodium glucose co-transporter-2 (SGLT-2) inhibitors like empagliflozin.
He has participated on a number of clinical practice guideline working groups, including with the European Society of Cardiology, UK Kidney Association, and K/DIGO. He is also interested in trial methodology and chaired the UK Renal Trials Network from 2020 2024.
His epidemiological research aims to better understand the key determinants of kidney disease development and progression (and its associated complications) using observations from large blood-based prospective cohorts across a wide range of different populations.
He has a particular focus on adiposity and its related risk factors, and how these may interlink to also cause cardiovascular disease. He is also focusing on how novel urine biomarkers could better assess effects of treatments on the kidney and predict progression.
Key publications
-
Empagliflozin in Patients with Chronic Kidney Disease
Journal article
HERRINGTON W. et al, (2022), New England Journal of Medicine
-
Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials
Journal article
HERRINGTON W. et al, (2022), The Lancet
-
Diabetes and Cause-Specific Mortality in Mexico City
Journal article
Alegre-Díaz J. et al, (2016), New England Journal of Medicine
-
Journal article
Baigent C. et al, (2011), Lancet, 377, 2181 - 2192
-
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
Journal article
Herrington W. et al, (2016), The Lancet Diabetes and Endocrinology
Recent publications
-
Journal article
ZHU D. et al, (2024), NDT International
-
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
Journal article
Mayne K. et al, (2024), Nephrology Dialysis Transplantation
-
Journal article
Herrington WG. and Haynes R., (2024), N Engl J Med, 391, 178 - 179
-
Journal article
Collister D. et al, (2024), Nephrol Dial Transplant
-
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
Journal article
Mayne K. and HERRINGTON W., (2024), American Society of Nephrology. Clinical Journal